Drug-induced hypomelanosis (Q83168): Difference between revisions

← Older edit

@@ Property / CURIE @@
+CID11:ID_1913292067
@@ Property / CURIE: CID11:ID_1913292067 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-ID_1913292067
@@ Property / Canary Token: dki-india-ID_1913292067 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank

Latest revision as of 08:32, 15 August 2026

Focal or generalised loss of epidermal pigment attributable to pharmacologically active topical or systemical agent. This may be intentional with topical use of hydroquinone or monobenzylether of hydroquinone used with the intention of reducing skin pigmentation temporarily or permanently respectively. It is a rare side effect of chloroquine and hydroxychloroquine and has been described with the tyrosine kinase inhibitor, imatinib.

Language	Label	Description	Also known as
default for all languages	ID_1913292067
English	Drug-induced hypomelanosis	Focal or generalised loss of epidermal pigment attributable to pharmacologically active topical or systemical agent. This may be intentional with topical use of hydroquinone or monobenzylether of hydroquinone used with the intention of reducing skin pigmentation temporarily or permanently respectively. It is a rare side effect of chloroquine and hydroxychloroquine and has been described with the tyrosine kinase inhibitor, imatinib.